24 November 2023 | Friday | News
Under the terms of the agreement, CR Sanjiu will be responsible for the hospital, pharmacy and e-commerce channel distribution and promotion of STADA's well-established cough and cold syrups in China. Among these are the Shidagong, Gelite, Ruike and Xikening brands which STADA produces at a dedicated 13,250 sq m facility in Miyun, near Beijing, China.
Furthermore, the partnership is also intended over time to act as a multi-category platform from which to introduce other STADA consumer healthcare products that will be promoted and distributed by CR Sanjiu through its network of more than 2,000 sales representatives and e-commerce platforms, serving 400,000 pharmacies and thousands of public hospitals nationwide.
“Expanding our presence and service to customers in China’s cough and cold consumer healthcare market is a key strategic target for STADA,” explained STADA’s Head of Emerging Markets, Stéphane Jacqmin. “With CR Sanjiu, we are convinced we have found an ideal partner to achieve this goal.”
STADA Global Head of Consumer Healthcare, Volker Sydow, added: “China is a growing and strategically important market for STADA’s Consumer Healthcare product segment. Working closely with CR Sanjiu to promote our cough and cold range through trusted retail partners perfectly complements the cross-border e-commerce presence we have built up in China with brands including Eunova multivitamins and the Viscontour skincare and beauty line.”
For CR Sanjiu, adding STADA’s highly reputed cough and cold brands to its promoted portfolio diversifies its offering to consumers, hospitals and retail partners whilst complementing the company’s existing range of respiratory products. The partnership with STADA aligns with CR Sanjiu's strategic goals and category development plan as well as its ambition to collaborate only with trusted partners such as STADA.
© 2024 Biopharma Boardroom. All Rights Reserved.